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We substantiate our preliminary description of the class I
tryptophanyl-tRNA synthetase minimal catalytic domain with
details of its construction, structure, and steady-state kinetic
parameters. Generating that active fragment involved deleting
65% of the contemporary enzyme, including the anticodon-
binding domain and connecting peptide 1, CP1, a 74-residue
internal segment from within the Rossmann fold. We used pro-
tein design (Rosetta), rather than phylogenetic sequence align-
ments, to identifymutations to compensate for the severe loss of
modularity, thus restoring stability, as evidenced by renatur-
ation described previously and by 70-ns molecular dynamics
simulations. Sufficient solubility to enable biochemical studies
was achieved by expressing the redesignedUrzyme as amaltose-
binding protein fusion. Michaelis-Menten kinetic parameters
from amino acid activation assays showed that, compared with
the native full-length enzyme, TrpRS Urzyme binds ATP with
similar affinity. This suggests that neither of the two deleted
structural modules has a strong influence on ground-state ATP
binding. However, tryptophan has 103 lower affinity, and the
Urzyme has comparably reduced specificity relative to the
related amino acid, tyrosine. Molecular dynamics simulations
revealed how CP1 may contribute significantly to cognate
amino acid specificity. As class Ia editing domains are nested
within the CP1, this finding suggests that this module enhanced
amino acid specificity continuously, throughout their evolution.
We call this type of reconstructed protein catalyst an Urzyme
(Ur prefix indicates original, primitive, or earliest). It establishes
a model for recapitulating very early steps in molecular evolu-
tion in which fitness may have been enhanced by accumulating
entire modules, rather than by discrete amino acid sequence
changes.
Aminoacyl-tRNA synthetases (aaRS)2 include two super-
families, each consisting of 10 members. Both aaRS classes
catalyze amino acid activation, the most difficult reaction in
protein synthesis, and thus are crucial to understanding the
origin of the proteome. As suggested by their name, their chief
function is to synthesize specific aminoacyl-tRNAs (Reaction
2), in effect translating the genetic code (2). In the absence of
these biological catalysts, the first half of this reaction, amino
acid activation by ATP (Reaction 1) occurs at a rate of 8.3 
109/mol/s (as corrected from the published value of 7 106/
mol/min for reaction at pH 9.7, 39 °C for a similar reaction (3)).
This represents, bymany orders of magnitude, the highest acti-
vation energy barrier of any reaction required for protein syn-
thesis. Hence, although the specificity of tRNA aminoacylation
eventually became the hallmark activity of these enzymes (4),
the emergence of amino acid-activating enzymes is probably
themost significant requirement for launching the evolution of
protein synthesis.
aaRS  ATP  aa  (aa-AMP)aaRS  PPi
REACTION 1
(aa-AMP)aaRS  tRNA  aa-tRNA  AMP  aaRS
REACTION 2
aaRSs very likely evolved from simpler polypeptide chains
into complex multidomain, multifunction contemporary
enzymes by progressively accumulating additional modular
genetic information (5, 6), whosemost obvious selective advan-
tages arose from their ability to enhance catalytic activity and
fidelity. Application of Ockham’s razor suggests that vestiges of
earlier forms should remain in contemporary enzymes. Struc-
tural analyses indicate that both class I and II aaRSs contain
small (120 amino acids) catalytic cores (2) complemented by
internal insertions and external domains. We refer to con-
structs derived from these putative ancestral enzymatic cores as
Urzymes, from Ur meaning primitive, earliest, or original plus
enzyme. This term emphasizes that such constructs represent a
ubiquitously conserved, dramatically smaller, and catalytically
active polypeptide containing the active site of the correspond-
ing native enzyme.
As Urzymes are identified by tertiary structural superposi-
tion, they should be distinguished from ancestral nodes resur-
rected from multiple sequence phylogenies (7–10). Genes res-
urrected in this manner represent earlier versions of what are
essentially contemporary proteins. Urzymes, on the other
hand, possibly represent the earliest protein catalysts.
One of the most striking successes of ancestral gene resur-
rection comes from work on the steroid hormone receptors (7,
* This work was supported, in whole or in part, by National Institutes of Health
Grant GM078227.
1 To whom correspondence should be addressed: 3092 Genetic Medicine,
120 Mason Farm Rd., Chapel Hill, NC 27599-7620. Fax: 919-966-2852;
E-mail: carter@med.unc.edu.
2 The abbreviations used are: aaRS, aminoacyl-tRNA synthetases; TrpRS, tryp-
tophanyl-tRNA synthetase; CTD, C-terminal (anticodon binding) domain;
CP1, connecting peptide 1; DES, redesigned TrpRS Urzyme; MD, molecular
dynamics; MBP, maltose-binding protein; SUMO, small ubiquitin-related
modifiers.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 285, NO. 49, pp. 38590 –38601, December 3, 2010
© 2010 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
38590 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285 • NUMBER 49 • DECEMBER 3, 2010
11). The authors (7, 11) used sequences derived by statistical
inference from phylogenetic analysis of multiple sequence
alignments to construct an ancestral gene. Then, by making
multiple point mutations, Thornton and co-workers (11) mod-
ulated the receptor specificity for different ligands in keeping
with the chronological divergence of ligand specificity along the
phylogenetic tree. Finally, they built and tested a progressive set
of mutations mimicking the evolution of the two descendant
receptors, revealing that some of thesemade the pathways irre-
versible (12).
The TrpRS Urzyme construction was motivated by objec-
tives shared with those of ancestral gene resurrection (8),
namely to study the recapitulation of putative evolutionary
events. In the case of the aaRS, such events include the devel-
opment of amino acid specificity, the emergent ability to acylate
tRNAs, and the subsequent development of cognate tRNA
specificity. To mimic changes associated with these activities
that might have occurred early along the evolution leading to
contemporary enzymes, it is especially important that the
effects of those changes also be measurable. This study docu-
ments the authenticity of such experimental measurements.
Of particular interest for this work is an inserted domain of
variable length within the Rossmann dinucleotide binding fold
in class I aaRS, called connecting peptide 1 (CP1) (1, 13). In
TrpRS, the smallest class Ic aaRS, the CP1 insertion has only 74
residues and has no editing activity. However, data provided
here point to the possibility that CP1 does indeed enhance
amino acid specificity. Moreover, in three of the large class Ia
aaRSs (LeuRS, IleRS, and ValRS), the corresponding internal
insertion has grown into an independently structured domain
harboring the editing function that is specific for the most fre-
quently mistaken naturally occurring amino acids (14–17),
thereby amplifying the fidelity of aminoacylation in those con-
temporary class I enzymes.
Simultaneous emergence of two classes of aaRSs has been
rationalized by a unique hypothesis proposed by Rodin and
Ohno (18). Based onmultiple sequence alignments, they found
that the codons for theHIGH andKMSKS class I signatures are
very nearly antisense to the corresponding codons of the class II
motifs 2 and 1, respectively. In other words, when the interven-
ing CP1 insertions are removed, the KMSKS and HIGH loops
can be approximately aligned, antiparallel with motif 1 and 2,
suggesting that the class I and II core catalytic apparatuses
could once have been gene products from the sense and anti-
sense strands of one gene. The earliest aaRS would have been
active enzymes; otherwise, they could not have participated in
natural selection. The Rodin/Ohno observation therefore pre-
dicts that an appropriately constructed class I aaRS gene lacking
CP1 and the C-terminal anticodon-binding domain (CTD)
should be enzymatically active. However, until recently (19), no
experiment had been done to test that prediction.
In our previous paper (19), we presented a preliminary
description of such an experiment, inwhichwedeleted both the
C-terminal anticodon-binding domain and the CP1 peptide,
fusing together the first and second halves of the TrpRS Ross-
mann fold. The resulting 130-residue fragment contained a
nearly intact active site in which the TIGN and KMSKS signa-
tures are separated by approximately the same number of
amino acids as class II motifs 2 and 1, respectively. Two con-
structs were expressed, one with a nearly native sequence and
the other with 12 mutations from a re-design by Rosetta (20).
Both were insoluble. However, the re-designed construct
(DES), but not the native one (WT), could be renatured. Its
specific activity represented at least a 109-fold increase over the
uncatalyzed rate, which is within 5 orders of magnitude of the
native TrpRS activity (19).
This paper follows up that work (19) by describing important
and previously unreported details of the design process, evi-
dence regarding the DESTrpRSUrzyme structure frommolec-
ular dynamics (MD), and an expression system that produces
that construct in soluble form. Having sufficient quantities of
soluble DES-TrpRS, Urzyme has enabled us to titrate the frac-
tion of active sites and determine Michaelis-Menten parame-
ters, which differ markedly from those of the full-length
enzyme, reinforcing the conclusion that the observed activity
arises from the Urzyme itself.
EXPERIMENTAL PROCEDURES
Linker Design to Replace Connecting Peptide 1—The TrpRS
Urzymes described in Pham et al. (19)were constructed in silico
by fusing two halves of the Rossmann fold. Connecting peptide
1, a 74-residue-long fragment between Thr-46 and Gly-121,
and the last 124 amino acids of the C-terminal domain were
removed. The resulting 130-residue sequence was submitted to
Rosetta designwith six alternative linkers (A,AA,AGA,AAAA,
AAGAA, and AGAAGA) between the disjoint active-site frag-
ments. These linkers varied in length and consisted of short side
chain amino acids alanine and glycine. A zero length linker was
also included. For each linker, 60 backbone templates were
identified to restoremolecular continuity and designed to opti-
mize the energy scores. To preserve the wild type sequence as
far as possible (WTUrzyme),mutations were allowed in up to 4
residues adjacent to each side of CP1 removal.
To improve solubility, solvent-accessible surface areas of side
chains in the TrpRS Urzyme were compared with correspond-
ing side chains in native full-sized TrpRS in three different con-
formations, the open unliganded state, the pre-transition state,
and the closed, liganded product state, using Areaimol (21). A
threshold increase of 50 Å2 in exposure of hydrophobic resi-
dues caused by CP1 and CTD removal was used to identify
residues that would be subjected tomutation by Rosetta design.
Twelve predictedmutations were introduced to theWTTrpRS
Urzyme in addition to those previously selected for CP1 loop
closure to construct the redesigned (DES) Urzyme. Genes for
both TrpRSUrzyme amino acid sequences were synthesized by
Genscript, who eliminated rare codons from the synthetic
genes.
Subcloning—Restriction enzymes and other molecular biol-
ogy reagents were obtained from New England Biolabs and
were used according to the manufacturer’s protocols. Forward
and reverse primers for PCR amplification were designed to be
complementary to the Urzyme sequence, containing extra
nucleotides coding for N-terminal FLAG and C-terminal His6
tags. Desired restriction sites were also introduced in the
primer design step. Following digestion with the appropriate
restriction enzymes, the PCR products were cloned to Esche-
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richia coli expression plasmids pET SUMO (Novagen) or
pMAL-c2x (New England Biolabs) for use in bacterial strain
BL21(DE3)pLysS (Novagen). All constructs were confirmed by
DNA sequencing.
Expression and Purification of MBP Fusion—MBP-TrpRS
Urzyme fusion was expressed directly after transforming with
plasmid DNA. After transformation, 100 l of competent cells
were incubated in 1ml of LBmedia at 37 °C for 1 hwith shaking
and then used to inoculate 100ml of growthmedia (LB plus 2%
glucose, 100 mg/ml ampicillin). The inoculum was shaken at
250 rpm overnight at 37 °C and then transferred to 1 liter of
fresh LBwith 100mg/ml ampicillin. AtA600  0.4–0.6, isopro-
pyl -D-thiogalactopyranoside was added to 0.3 mM final con-
centration to induce gene expression. Harvest began 3 h after
induction.
Cells were collected by centrifugation at 4,500 rpm for 20
min at 4 °C and then resuspended in lysis buffer (50 mM Tris,
10% sucrose, pH 7.5). After overnight storage at 80 °C, the
cells were thawed on ice and lysed by sonication in pulse mode
(three times for 15 s). The lysate was centrifuged at 14,000 rpm
for 30min at 4 °C to separate the supernatant fraction from the
inclusion bodies. The supernatant from this stepwas diluted 1:5
with the amylose resin High Flow (New England Biolabs) col-
umn buffer (20 mM Tris-HCl, 0.2 M NaCl, 1 mM EDTA, 10 mM
-mercaptoethanol, pH 7.4) before loading onto a disposable
column (Bio-Rad) containing 2ml of amylose-conjugated resin
suspension for each 10 ml of the diluted supernatant. The col-
umnwas equilibratedwith 3 column volumes of column buffer,
and the resin was washed with 5 column volumes. The flow-
through fraction was collected, and then the resin was washed
with 8 column volumes of column buffer to minimize nonspe-
cific binding. The bound fusion protein was eluted in 1.5-ml
fractions with elution buffer (column buffer plus 10 mM malt-
ose). The first five fractions were combined and dialyzed three
times overnight against 10 volumes of 50% glycerol dialyzing
buffer (20 mM Tris-HCl, 50 mM KCl, 0.1 mM PMSF, 10 mM
-mercaptoethanol, 50% glycerol, pH7.5) at 4 °C. Sampleswere
stored at 20 °C after dialysis.
Factor XaCleavage—TheMBP fusionwas digestedwith Fac-
tor Xa (New England Biolabs) overnight at 4 °C with rotation.
The ratio of protease to fusion protein is 1:50 (v/v). Concen-
trated fusion proteinwas diluted to a final concentration of 10%
glycerol from stock stored in 50% glycerol before digestion. The
digestion mixture was used directly for tryptophan activation
assay.
Active-site Titration—The concentrations of active sites,
compared with the total concentrations of DES TrpRS fusion
protein and Urzyme, were determined using the active-site
titration procedure as described previously (22) using 10 mM
[-32P]ATP in excess over the total estimated enzyme concen-
tration (1.7 mM). Reactions were quenched with SDS at time
intervals between 3 and 45 min and aliquots examined using
thin layer chromatography on polyethyleneimine cellulose.
After development, plateswere scanned using aTyphoon phos-
phorimager. Amounts of labeled ATP and PPi were estimated
from densitometry and fitted to Equation 1 using JMP (23).
ATP  Aexp(kchemt  kcatt  C} (Eq. 1)
The active fraction is obtained from the fitted parameters
(24) as shown in Equation 2.
n  1.07	1/	1  CATPtotal/enzymetotal (Eq. 2)
ATP- and Tryptophan-dependent 32PPi Exchange Assays for
Tryptophan Activation—Samples were assayed using the tradi-
tional 32P-pyrophosphate exchange as described previously (25,
26) except that a 3-fold reduction of background 32P countswas
achieved by collecting the charcoal containing labeled ATP on
disposable spin columns, washing, and eluting the bound ATP
with 50 l of pyridine at 37 °C (19). ATP and tryptophan were
first depleted from the assay buffer to determine ATP- and
tryptophan-dependent Michaelis-Menten constants. Stocks of
ATP and tryptophan were added to the depleted buffer at indi-
cated concentrations. Activity measurements and substrate
concentrations were fitted to the Michaelis-Menten equation
using JMP (23). The kcat value was based on the estimated con-
centration of TrpRS Urzyme released after 80% efficient Factor
Xa digestion, using the ImageJ image-processing program
(National Institutes of Health) to obtain the relative densities of
proteins on a Coomassie-stained SDS-polyacrylamide gel and
corrected for the fraction of active sites.
Molecular Dynamics Simulations—The structure output by
Rosetta for the DES TrpRS Urzyme was used to construct the
initialmodel forMD simulations using the Sigma program.The
final system contained 2157 protein atoms, including hydrogen
atoms and 4684 water molecules, described by the CHARMM
force field and TIP3P water model, respectively, as described
previously (27).
RESULTS
As we were interested in more radical protein surgery neces-
sary to remove the CP1 peptide and the anticodon-binding
domain, our approach should be distinguished from ancestral
gene resurrection. Information about possible amino acid
sequences of long extinct prototypic enzymes necessary to test
the Rodin and Ohno hypothesis has vanished. The challenge
therefore lies in identifying compensatory amino acid muta-
tions in the remaining polypeptide to create a model for the
ancestral enzyme. Those sequences cannot be assumed to
resemble contemporary proteins because large masses must be
deleted, and in the case of the TrpRS Urzyme, removing these
masses cleaves several of the chief hydrophobic cores from
which the contemporary protein derives its stability.Moreover,
exposure of the cleaved nonpolar cores leads inevitably to
aggregation and low solubility.
TrpRS is, nonetheless, a nearly ideal system with which to
attempt this radical protein surgery. It is the smallest aaRS, and
the gap between the two free ends resulting from CP1 removal
is only 5 Å long, which can be joined directly by relaxing the
adjacent backbone. We used the biophysical chemistry imple-
mented in the protein design program Rosetta (20) to approx-
imate sequence changes involved in the putative evolutionary
process, which have faded from the amino acid sequence
phylogenies.
Computational Design Ensures TrpRS Urzyme Molecular
Continuity, Stability, and Solubility—Two genes encoding the
highly conserved residues in two disjoint fragments of the
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TrpRS Rossmann fold were constructed (19) based onmultiple
structure alignments of known class I aaRSs. In both these 130-
amino acid Urzymes, the connecting peptide (CP1) was re-
moved; the N- and C-terminal crossover connections of the
Rossmann fold were ligated, and the C-terminal domain was
truncated at residue 204.
These deletions exposed the molecule to two anticipated
problems. The first of these was structural disruption at the site
of CP1 removal. To reconnect the two disjointed active-site
fragments, we used the Rosetta LOOP algorithm to substitute
short data base-derived linkers of varying length, from 0 to 6
residues, containing the short side chain amino acids alanine
and glycine to minimize interactions between the inserted side
chain and the main backbone. These were scanned to identify
optimal backbone continuity between the N- and C-terminal
fragments of the Urzyme (Fig. 1). Furthermore, four residues
adjacent to sites Thr-46 and Gly-121, where CP1 was removed,
were allowed to mutate (with backbone relaxation), facilitating
the joining of two free ends. This construct also had five muta-
tions, illustrated by the line of blue spheres at the site of removal
(Fig. 2B).
It is notable that of all seven linkers tested, ranging from 0 to
6 amino acids, the direct linkage between Thr-46 and Gly-120
was consistently predicted by Rosetta to be most stable (Fig. 1).
This result is consistent with the presumed existence of an
ancestral class I aaRS lacking the connecting peptide 1, and
suggests that CP1 was a later insertion.
More severe problems were instability and/or insolubility
due to the loss of two-thirds of the stabilizing mass afforded in
the full-length TrpRS. Disruption of nonpolar core packing is
exacerbated because in class I aaRS the region forming the chief
hydrophobic core inmany canonical Rossmannoid proteins has
been evacuated to accommodate the amino acid-binding site
(Fig. 2A). Thus, a significant portion of the TrpRS hydrophobic
core resides in the interface between the Urzyme and CP1 and
becomes exposed by removing CP1.
An exception is a 7-residue core at the C terminus of the
N-terminal -helix of the Rossmann fold. We have noted that
this core motif likely participates in conformational switching
and transition state stabilization in native TrpRS (28). Notably,
this motif remains intact in the TrpRS Urzyme.
Elsewhere, however, deletions made in constructing the
Urzyme uncovered a large number of buried nonpolar side
chains. Because of this problem, we were unable to refold the
WT TrpRS Urzyme without generating extensive aggregation,
as evidenced by heavy precipitation as the 6 M urea was dialyzed
away (19).
To address the instability and insolubility resulting from
exposing core side chains, the profile of the accessible surface
area for each residue in the computationally simulated Urzyme
was compared with the native enzyme using Areaimol (21).
From 60 residues with increased surface area after removal of
CP1 and the CTD, the 19 residues with the greatest percentage
increase in surface area were selected, and Rosetta was run to
identify the mutations (Table 1).
Of those 19 residues, 12 mutations predicted by the design
program to improve solubility and stability were included in a
second construct. Except for Tyr-91, these mutations all were
made to nonconserved residues. The two TrpRS Urzyme con-
structs in Fig. 2, designated wild type (WT) and redesigned
(DES), were synthesized after the two phases of linker design
and stability-solubility optimization (19).
Rosetta design has a tendency to place patches of hydropho-
bic residues together (29). Thus, its ability to improve Urzyme
solubility was somewhat less than its ability to recover stability
and proper folding. Nevertheless, of themutations predicted to
stabilize and solubilize the DES TrpRS Urzyme, five are from
hydrophobic to hydrophilic (Fig. 2B) and would directly
improve the interaction with solvent.
The redesigned TrpRS Urzyme also expressed predomi-
nantly in inclusion bodies. However, in contrast to the WT
Urzyme, we were readily able to refold it from 6 M urea by
successive dialysis to remove (19) and to demonstrate its cata-
lytic activity. Thus, Rosetta afforded a decisive advantage in
stability and, presumably, correct folding (19).
SUMO Expression System Improved Yield but Not Solubility,
although theMajority ofMBPFusion ProteinWas in the Soluble
Fraction—Both WT and DES TrpRS Urzymes were insoluble
when expressed as pET42 constructs. Subcloning the two genes
into Invitrogen pET small ubiquitin-related modifier (SUMO)
vector improved the expression level, but the SUMO fusions
stayed insoluble in the pellet (Fig. 3A, P). The size of SUMO-
fused redesigned Urzyme estimated by SDS-PAGE was at the
expected position of 25 kDa. TrpRS Urzyme accounted for
56% the mass of the fusion, which suggested that the 11-kDa
SUMO carrier may be too small to overcome the insolubility of
the Urzyme. No effort was made to measure enzymatic activity
from the SUMO fusions.
Maltose-binding protein (MBP) is approximately three
times larger than the subcloned open reading frame of TrpRS
Urzyme. A linearized pMAL-c2x map used for subcloning is
shown in Fig. 3B. The construct was doubly tagged with the
FIGURE 1. Rosetta energy scores are decisively lower for the 130-residue
Urzyme with a zero length linker (direct linkage between Thr-46 and
Gly-121) and five relaxed side chains adjacent to the site of CP1 removal.
Multiple designs for each of six other possible linker lengths are shown in
colors ranging to red (the worst). The designed sequence indicated by the
blue asterisk is the subject of this work.
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N-terminal FLAG and C-terminal
His6. Immunoblots of soluble (super-
natant) and insoluble (pellet) frac-
tions with anti-FLAG antibody
showed that the majority (80%) of
the fusion was in the supernatant
(data not shown). Affinity chroma-
tography on amylose resins gave
pure, soluble fusion protein (Fig.
3B). Because of the low catalytic
activity of the Urzyme, data such as
that in Fig. 3B do not adequately
describe purity with respect to very
minor contaminating amounts of
native E. coli TrpRS, which must be
addressed by other controls. These
are summarized below.
The MBP fusion protein ap-
peared to be inactive in the initial
tryptophan activation assay (data
not shown). Factor Xa cleavage of
the fusion protein released about
80% of the Urzyme from the MBP
fusion. Several assays on inactive
cleaved preparations showed no
activity, ruling out activity arising
from Factor Xa. The digestion mix-
ture was used directly for 32PPi ex-
change assays, showing that di-
gestion also released a cryptic
tryptophan activating activity from
the fusion protein.
A major concern has been the
degree to which the Urzyme con-
structs fold properly. We used this
activity to address that question
here as follows: first by carrying out
active-site titration (24) of both
fusion protein and Urzyme, sec-
ond by Michaelis-Menten steady-state assays and determi-
nation of relative specificity for tryptophan versus tyrosine,
and finally by carrying out long molecular dynamics simula-
tions. Many factors likely impact the activity and properties
of the TrpRS Urzyme, and we have managed only to control
some of these. Thus, all experimental measurements are sub-
ject to high variance. Thus, it is difficult, for example, to
compare the experiments that follow on a quantitative basis
because they have been done with different Urzyme prepa-
rations. Nevertheless, we document here three conclusions
that lie well beyond experimental error. (i) Active-site titra-
tion experiments show that previous estimates for the
Urzyme activity are lower limits and that the actual activity is
higher, because of the fact that only 35% of the molecules
are active. (ii) Michaelis-Menten experiments show that
both kcat and the affinity for ATP are close to corresponding
values for the full-length enzyme. (iii) Weaker amino acid
affinity in the Urzyme leads to significantly reduced amino
acid specificity.
FIGURE 2. A, comparison of nonpolar cores in TrpRS Urzyme (center) and catalytic domain (right) with the
canonical Rossmannoid homolog, FixJ (left). All structures were superimposed using the 46 residues of the
N-terminal -- crossover connection (42). Note the location of the two substrates, ATP (green) and trypto-
phan (magenta). Tryptophan occupies a region which, in FixJ, contains a substantial hydrophobic core. Migra-
tion of the core away from the interface between the central -sheet and the helix to accommodate the amino
acid substrate heightens difficulties posed by stripping away the CP1 peptide and anticodon-binding domain,
making protein design more critical to class I Urzyme construction. B, schematic of mutations introduced to the
TrpRS Urzymes, including five residues that were changed from hydrophobic to hydrophilic in the WT and DES
Urzymes, respectively (boldface). Free energy differences were also calculated showing minimal effect of the
mutations. A 
Gstat of less than 0.45 is a measure of relative sequence conservation as defined by Lockless and
Ranganathan (60). The redesigned Urzyme harboring 12 mutations (Table 1) is predicted to improve stability
and solubility (adapted from Pham et al. (19)).
TABLE 1
Solvent-accessible surface area between WT Urzyme and full-length
TrpRS
Three different configurations are compared as follows: PROD, Trp-5AMP complex;
Pre-TS, pre-transition state complex to ATP and tryptophanamid; open, unliganded.
Amino acid Residue S(Prod) S(Pre-TS) S(open)
Val 13 9 99 19
Ile 14 85 71 102
Ile 16 57 62 58
Tyr 19 98 74 83
Leu 23 57 56 63
Tyr 36 90 86 65
Phe 37 84 88 95
Ile 39 124 127 124
Leu 122 132 120 89
Leu 123 115 119 117
Leu 135 130 119 112
Tyr 136 87 81 91
Leu 153 64 58 56
Leu 157 52 55 51
Phe 161 72 75 76
Tyr 165 89 80 74
Leu 168 75 76 69
Leu 186 105 91 109
Ile 204 114 119 134
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Nearly 90% of the surface area buried in the full-length
TrpRS dimer arises from the deletedCP1 peptide.On this basis,
we expect that the Urzyme is active as a monomer. Attempts to
confirm this conclusion definitively have been inconclusive,
because gel filtration patterns of both the MBP fusion protein
and the cleaved products under native solution conditions are
broad and of elevated molecular weight, implying nonspecific
aggregation.
Active-site Titration Clarifies the Relative Activities and
Folding of the DES Fusion Protein and Urzyme—Active-site
titration experiments provide several key clarifications. First,
they confirm that even after such drastic surgery on the native
TrpRS structure, product release remains rate-limiting for the
Urzyme. This was certainly not a foregone conclusion, as
removal of an entire domain and the CP1 subdomain could
have abolished the ability of the Urzyme to retain the adenylate
intermediate and hence to exhibit a pre-steady-state burst. The
titration experiments show convincingly that substantial bursts
occur (Fig. 4).
Second, titrations provide estimates of the degree of proper
folding. The algorithm described by Fersht et al. (24) affords an
estimate that about 81% of the fusion proteins and 35% of the
cleaved Urzyme preparations have competent active sites.
These estimates narrow the range of values for kcat reported
below. Absent the active-site titrations, values we obtained
would necessarily only be lower limits.
Finally, titrations confirm that the fusion protein is inhibited
by the MBP tag. Thus, although the fusion protein has a higher
fraction of active sites, its kchem value is about a third that of the
cleavedUrzyme, in keepingwith our recurrent inability to dem-
onstrate steady-state activity in fusion protein preparations.
TrpRS Urzyme Tryptophan Activation Activity Depends on
Both ATP and Tryptophan—Michaelis-Menten experiments
substantiate the use of the TrpRS Urzyme to represent ances-
tral aaRS activity (Fig. 5). Therewas no activity in the absence of
either tryptophan or ATP. The specific activity previously esti-
mated from the specific activity of refoldedDESTrpRSUrzyme
expressed in pET42a plasmid was 105 times weaker than that
of the full-length enzyme (19). As a result of the low activity,
steady-state kinetics experiments reported here for the fusion
protein and cleaved products were noisy, and titrations with
both substrates were replicated multiple times.
Fig. 5 and Table 2 show that the DES TrpRS Urzyme kinet-
ics differ significantly from those of full-length TrpRS.
Moreover, the details themselves are interesting. The kcat
(4.9 s1) andKm values of Urzyme for ATP (0.4mM) are quite
similar to those of the full-length enzyme. The Km value for
tryptophan observed for Urzyme induced at 37 °C, 4.8 mM, is
2000 times weaker. Indeed, when
kcat is corrected for the active frac-
tion, the tryptophan Km value is by
far the most significantly different
between the full-length TrpRS and
its Urzyme.
Adventitious Contamination Can-
not Account for the Observed Ac-
tivity—Consistent with our earlier
report (19), steady-state kinetics
(Table 2) confirm that the catalytic
activity of the TrpRS Urzyme is a 4-
or 5-order ofmagnitudeweaker cat-
alyst than the full-length enzyme.
Under these circumstances, one
must do everything possible to
ensure that the observed activity
arises from the Urzyme and not
FIGURE 3. A, SUMO expression system increases total Urzyme production but not
solubility. M, molecular weight markers; NI, noninduced control; S, supernatant; P,
pellet. B, expression and purification of maltose-binding protein-fused rede-
signed TrpRS Urzyme. I, induced expression; S, soluble fraction; FT, flow-through
fraction from amylose column; W, 1st wash after flow-through fraction; E1– 6,
eluted fractions; Et, concentrated fusion; Ec, Factor Xa cleavage products.
FIGURE 4. Active-site titration of DES TrpRS fusion protein (left) and Urzyme (right) expressed at 18 °C.
The [ATP] and [protein] were 10 and 1.7 mM, respectively. Both curves exhibit a pre-steady-state burst, from
which the fraction of active molecules can be estimated (24).
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from adventitious contamination. Co-purification of as little as
1 in 104–105 of chromosomal E. coli TrpRS could account for
the observed activity. The following experiments strongly sup-
port the conclusion that the activity reported here and earlier
(19) represents authentic catalysis by the Urzyme. (i) A pMAL-
c2x empty vector control extract purified by the same proce-
dure has negligible activity nor was there activity in several
unsuccessful efforts to purify the fusionprotein, consistentwith
the absence of contaminating wild type activity. (ii) Purifying
and renaturing the Urzyme from the insoluble inclusion body
fraction tends to eliminate contaminating soluble host cell
activity (19). (iii) Cryptic activity is released from the fusion
protein after Factor Xa cleavage (Fig. 4). (iv) Active-site titra-
tion reveals that activity arises from a significant fraction (35%)
of the potential active sites in the cleaved Urzyme sample. This
would clearly not be the case if a tiny fraction of contaminating
full-length enzyme were responsible for the observed steady-
state activity. (v) The active site D146A mutation has opposite
effects on full-length TrpRS and the Urzyme. The mutation
reduces the activity of the full-length enzyme 200-fold, but it
increases that of the Urzyme 25-fold (19). (vi) TheKm, Trp value
for urzyme (Fig. 5 andTable 2) is2000-fold higher than that of
the full-length enzyme. If contaminating E. coli TrpRS were
responsible for the activity, it would saturate at 2 M, not at
much higher tryptophan concentrations.
TrpRS Urzyme Has a Structure Similar to That Observed in
the Full-length Enzyme—As yet, we have limited structural data
for the TrpRS Urzyme. The redesigned Urzyme still has low
solubility when cleaved from the MBP fusion. However, the
tertiary structure derived from Rosetta design is stable in 70-ns
molecular dynamics calculations
(Fig. 6, A and B), suggesting that the
observed catalytic activity derives
from a structure similar to that
expected from the structure of the
full-length enzyme from which it is
derived. Moreover, as described
more fully below, MD simulations
help rationalize the significant dif-
ferences in Trp affinity between the
Urzyme and full-length TrpRS.
High Km Value of Urzyme for
Tryptophan Implies ReducedAmino
Acid Specificity—Although the resi-
dues lining the ATP and tryptophan
binding pockets are nearly all pre-
served in the Urzyme, the trypto-
phan affinity is 103-fold weaker.
Weak amino acid binding strongly
suggests that the Urzyme has significantly reduced amino acid
specificity, relative to the contemporary enzyme. To test this
notion, we examined the specificity ratio, (Vmax/Km)Trp/(Vmax/
Km)Tyr (Table 3). The Urzyme is 500-fold less specific than
full-length TrpRS for tryptophan relative to the related amino
acid tyrosine. This result suggests a rather unexpected view of
the ancestral TrpRS Urzyme, in which ATP bound tightly but
tryptophan had only modest affinity.
A possible explanation is that longer range stabilizing in-
teractions eliminated by removing the connecting peptide 1
and perhaps also the C-terminal anticodon binding domain
significantly decrease an unfavorable entropy change neces-
sary for amino acid binding to theUrzyme. Consistent with this
hypothesis, long MD trajectories of the Urzyme complexed
with Mg2ATP with and without tryptophan (Fig. 6B) reveal
that the native-like orientation of the D helix, which we have
referred to as the “specificity-determining helix” because it pro-
vides several residues crucial to specific amino acid recognition,
depends strongly on bound tryptophan. In the absence of tryp-
tophan, this helix deviates quite far from its position in the
native enzyme, leading to a divergent trajectory. The presence
of bound tryptophan preserves its native-like orientation.
Fig. 6C highlights the fact that CP1 surrounds and constrains
the orientation of the specificity-determining helix. It appears
to serve as an exo-skeleton that stabilizes the configuration of
the tryptophan binding pocket. The MD trajectories therefore
provide a persuasive rationale for the observed weakening of
amino acid binding by the Urzyme and the consequent loss in
fidelity.
DISCUSSION
The TrpRS Urzyme represents achievements in protein bio-
physics and biochemistry, and its measurable catalytic activity
establishes a basis for experimental studies of the very early
evolution of biological catalysis and molecular biology. We
begin by discussing how in silico protein design used to con-
struct the TrpRS Urzyme (19) extends previous efforts to dis-
sect catalytically active domains from native, full-length pro-
FIGURE 5. Steady-state kinetic analysis of 32PPi exchange activity of TrpRS Urzyme expressed at 37 °C.
A, ATP dependence is similar to that of full-length TrpRS. B, tryptophan dependence does not saturate at
accessible tryptophan concentrations. Error bars show standard deviations of measurements made at the same
substrate concentrations. Error estimates for kcat and Km are indicated in the insets. Prod, product.
TABLE 2









Km, ATP 0.0004  0.02 M 0.00041  0.12 M 1 M
kcat, ATP 27.2 s1 4.88  9.5 s1 0.18 s1
kcat/Km 68,000 Prod 11,902 s 0.18 M
Km, Trp 2.00 E–06 M 2.41 E–3  2.1 E–3 M 1205 M
kcat, Trp 26.5 s1 4.69  10 s1 0.18 s1
kcat/Km 13.2 E6 Prod 1.94 E3 s 1.5 E–4 M
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teins, and then consider mechanistic and evolutionary im-
plications of the Urzyme’s kinetic parameters.
Urzyme Construction Methods Substantially Extend the
Experimental Study of Mechanistic Enzymology andMolecular
Evolution—Rosetta designwas usedhere as a source formissing
phylogenetic data in TrpRS Urzyme construction. Ancestral
gene resurrection utilizes multiple sequence alignments to
deduce probable sequences for ancestral nodes. Because we
were interested in an analogous reconstruction from a much
more ancient period, phylogenetic data are insufficient to infer
sequences that might have stabilized ancestral fragments like
the TrpRS Urzyme. Nonetheless, natural selection for stability
(30)was a likely determinant of biological sequence alignments.
To that extent, Rosetta energy functions afford a sensible sur-
rogate for information missing from multiple sequence align-
ments, extending both the time frame and the modularity
accessible to the experiment. In this
way, protein design likely will
enhance what generally can be done
by protein surgery.
Previous efforts to generate ac-
tive fragments from contemporary
proteins have led to very diverse
constructs that retain varying lev-
els of catalytic activity.We referred
to the 130-residue TrpRS Urzyme
as a “minimal catalytic domain”
(19). At the other extreme, a 527-
residue fragment of acetylglu-
cosaminyltransferase V (70% of
the full-length enzyme) was also
referred to as a minimal catalytic
domain (31). We have coined the
term “Urzyme” to distinguish active
constructs that retain only sufficient
mass to position the active-site res-
idues for catalysis.
The domain structures of amino-
acyl-tRNA synthetases motivated
previous experimental truncations
to isolate active catalytic fragments
(32–35).These efforts focusedmainly
on cleaving between the catalytic
and anticodon-binding domains, a
widely documented approach ap-
plied routinely only to proteins
whose domain structures can be
readily identified (36–38). For
example, an N-terminal 320-resi-
due HisRS fragment (60% of the
native monomer) that retains an intact catalytic domain is 103-
fold less active without its deleted anticodon-binding domain
(32). Such truncations are far less aggressive than thosemade to
cognate tRNAs, which ultimately resulted in identifying mini-
helices 30% the size of intact tRNAs (39, 40) that could be
charged by several aaRS. At 40% of its native molecular weight,
the TrpRS Urzyme represents a comparable truncation for an
aaRS. Recapitulation experiments restore modular informa-
tion, such as CP1, whichwas removed to construct theUrzyme.
The Urzyme construction also resembles the joining of
domains from two related enzymes with different activities to
make an active fusion (41). The N-terminal fragment contains
the TIGN signature, together with a highly conserved core
packing motif (42) that we have implicated in conformational
switching (43) and activation of the catalytic Mg2 ion (28) in
full-length TrpRS. The C-terminal fragment contains residues
125–137,whichwepreviously termed the specificity-determin-
ing helix, as well as the GXDQ and KMSKS catalytic signatures.
The size of the resulting TrpRS Urzyme thus seems minimally
sufficient to position the active site residues.
Schwob and Söll (33) provided the most direct precedent for
this work. They selected in vivo for active truncations of the
class I aaRS GlnRS, developed by separate and nested deletions
of either the CP1 insertion or the anticodon-binding domain,
FIGURE 6. A, superposition of an MD snapshot of the TrpRS Urzyme after 1200 ps (blue) on the corresponding
pre-transition state structure derived from Protein Data Bank code 1MAU and complexed to both substrates.
The divergent segments are limited to the extreme C terminus following the catalytic KMSKS signature, which
aligns closely. B, 70-ns MD simulation trajectories of the Mg2ATP complex with and without tryptophan. The
presence of tryptophan stabilizes the Urzyme in a conformation close to that of the pre-transition state struc-
ture (black), although ATP alone favors a conformation closer to the open state of the full-length TrpRS (Protein
Data Bank code 1MAW). The inset highlights differences in the amino acid binding pocket between the two
trajectories. Re-orientation of the specificity-determining helix in the absence of tryptophan is noteworthy.
C, representation of CP1 (green spheres) wrapping around the core TrpRS Urzyme. Most interactions occur with
the amino acid binding pocket containing tryptophan (yellow). RMSD, root mean square deviation.
TABLE 3
Specificity ratios of full-length TrpRS and its Urzyme
Vmax/Km Specificity ratio
WT (Trp) 93,478 4328
WT (Tyr) 21.6
Urzyme (Trp) 547.1 10.0
Urzyme (Tyr) 54.9
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but not both. Their work demonstrated that various fusions of
the first and second halves of the Rossmann dinucleotide bind-
ing fold could preserve in vivo activity. Here again, our work
breaks new ground by deleting an entire CTD and fusing two
disjoint halves of the ATP-binding Rossmann fold after remov-
ing the 74-residue intervening CP1 peptide. Notably, in light of
our own similar difficulties, the GlnRS constructs could not be
assayed in vitro because they aggregated.
We note three important differences between the TrpRS
Urzyme and these GlnRS constructs. First, TrpRS Urzyme is
130 residues, compared with 460 residues in the minimal
GlnRS fragments. Second, the GlnRS CP1 deletions left intact
B- and C-helices with the intervening -strand, residues
71–115 (residues 49–96 in TrpRS), which are deleted entirely
in the TrpRS Urzyme without losing in vitro activating activity!
Finally, although both GlnRS constructs and the wild type
Urzyme aggregated irreversibly, redesign allowed us to over-
come the irreversible aggregation observed for both the GlnRS
constructs and the wild type Urzyme. Factor Xa cleavage of the
MBP fusion necessary to release the inhibited activity also led
occasionally to aggregation of the cleaved Urzyme, which was
exacerbated after longer incubation times, at higher tempera-
ture, and in the absence of glycerol. Aggregation remains a
problem to be addressed by further studies.
Accumulation of expressed WT and DES Urzymes in inclu-
sion bodies may contribute to the rapid loss of Urzyme-con-
taining plasmids, evenwhen selective pressure ismaintained by
using antibiotics. This apparent toxicity persists when the
Urzyme is expressed in BL21(DE3) pLysS, an expression system
that should minimize basal expression and hence toxicity.
Thus, some function, perhaps misacylation, probably occurs in
vivo and contributes to plasmid toxicity. Further work is neces-
sary to answer such questions.
The TrpRS Urzyme has potential applications for custom-
ized protein synthesis, which is of considerable interest (45, 46).
Suga and co-workers (47) have pioneered the use of ribozymal
acylating catalysts to incorporate noncanonical amino acids
into proteins for the purpose of protein engineering. Their
ribozyme, however, cannot activate amino acids. High catalytic
activity and low specificity make the TrpRS Urzyme a po-
tentially useful complement to this “flexizyme.” Functional
complementation between polypeptide and RNA catalysts in
such a context could model an important bridge between puta-
tive prebiotic RNA- and ribonucleoprotein-world scenarios.
Urzyme Enzymology (Urzymology) Reveals Cryptic Intramo-
lecular Interactions Necessary for Specificity and Catalytic
Activity—The 74-residue fragment 46–120 we refer to here as
CP1 previously was considered integral to the Rossmann fold.
The relative independence of TrpRSUrzyme function from the
three helices suggest altering the definition of theCP1 insertion
from that originally proposed (1, 13) to also include this frag-
ment. Indeed,CP1 is frequently used to refer only to the domain
structures suspended from a long, anti-parallel -arm that is
conserved only in class Ia and Ib aaRS. However, the 5-Å dis-
tance between the first and second crossover connections of the
Rossmann fold is distinctly conserved in all class I aaRS.
The significant impacts of removing CP1 and the CTD on
amino acid activating activity provide compelling evidence for
functional contributions of these modules in the full-length
enzyme. Our previous mutagenesis of the active-site lysine res-
idues in full-length TrpRS (28) suggest that rotation of the CTD
endows the catalytic Mg2 with a conditional role in catalysis.
The conditional use of metal ion catalysis ensures that catalysis
of amino acid activation is coupled to domain movements nec-
essary for tRNA aminoacylation. Although the switching resi-
dues we have identified in theN-terminal crossover connection
are retained in theTrpRSUrzyme, it is likely that addition of the
CTD allowed the evolutionary development of a more sophis-
ticated allosteric mechanism.
Parameters in Table 3 suggest that these contributions also
enhance substrate specificity, particularly the relative affinity
for different amino acid substrates. Contemporary full-length
TrpRS is very specific for its cognate amino acid substrate, tryp-
tophan (48), whereas the Urzyme is not. As noted above, CP1
surrounds the tryptophan binding pocket and forms nonpolar
cores on its three faces. A key role of the amino acid in the
Urzyme-catalyzed reaction appears to be to re-orient the spec-
ificity-determining -helix in the catalytically productive com-
plex, suggesting that much of the tryptophan-binding energy is
used to reconfigure the amino acid-binding site in the Urzyme,
consistent with its weaker affinity. It is tempting, especially in
light of the location of class Ia editing domains within CP1, to
relate the surprisingly weak tryptophan binding to the absence
of CP1 (Fig. 5C). The inserted CP1 appears to work as an
exoskeleton to stabilize the proper configuration necessary for
tryptophan recognition.
The CP1 helices form nonpolar cores with three regions sur-
rounding the tryptophan-binding site on the surface of the
Urzyme. Their substantial hydrophobic surfaces sustain terti-
ary structure throughout the class I superfamily. As a result,
removing CP1 creates a problem that is exacerbated by the fact
that the amino acid binding pockets in class I aaRS are created
at the expense of what in other Rossmannoid proteins is a sub-
stantial hydrophobic core (Fig. 2A). Stability of their tertiary
structures, especially those that define the amino acid binding
pocket, is thus necessarily exported to “outer sphere” core
regions between the Urzyme and the rest of the protein.
Other published work suggests CP1-induced specificity
enhancement derives from interactions between CP1 and the
amino acid binding pocket inTrpRS andmore generally in class
I aaRS. Praetorius-Ibba et al. (48) attempted unsuccessfully to
switch TrpRS specificity to favor tyrosine. Ten systematic
mutants within the tryptophan binding pocket left the relative
affinities for the two amino acids essentially unchanged. Their
lack of success suggests that longer range interactions are nec-
essary to stabilize the structure of the tryptophan binding
pocket for high affinity. Thus, the range ofmutations examined
previously (48) may have more dramatic effects on amino acid
discrimination by the Urzyme.
Similar attempts to change GlnRS binding specificity from
glutamine to glutamate have confirmed the importance of lon-
ger range interactions in configuring the amino acid binding
pocket (49, 50). As was observed for TrpRS, mutating only
amino acids that interact directly with the amino acid is insuf-
ficient to switch specificity. However, engineering of two exter-
nal loops and one deletion increase the generation of misacy-
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lated Glu-tRNAGln by GlnRS 16,000-fold. Both engineered
loops correspond to elements that interact closely with the
C-helix (GlnRS residues 102–116; TrpRS residues 83–97),
which is absent in the TrpRS Urzyme but present in the engi-
neered GlnRS. Our observations therefore reinforce the con-
clusion of Bullock et al. (49) that high amino acid specificity is a
distributed phenomenon and suggest that full recognition can
arise only in the presence of CP1.
It is likely, because of the significant role played by the tRNA
anticodon on tRNA recognition, that the CTD has a major
impact on interactions with cognate tRNA (51–53).We are not
yet in position to evaluate effects on tRNA specificity because
we have not yet tested the TrpRS Urzyme for tRNA acylating
activity. It lacks one tRNAdeterminant in the third helix of CP1
but retains residues 142–150 of the E helix, which is the other
element thought to include a tRNAacceptor-stem-binding site.
Thus, as catalysis of second-order reactions generally involves
reducing the entropy of activation, the Urzyme could possibly
accelerate the second, acyl-transfer, reaction. It is notable in
this respect that full-length TrpRS will actually acylate ATP,
which behaves as the ultimate “mini-helix.” The assay described
by Wolfson et al. (54) for tRNA acylation appears to have the
requisite sensitivity to detect catalyzed acyl transfer at levels
comparable with that observed for tryptophan activation.
Opposite Effects of the D146AMutation in Full-length TrpRS
and the Urzyme Imply Mechanistic Differences—ATP-depen-
dent Michaelis-Menten parameters for the Urzyme appear to
be quite similar to those of the intact enzyme. Thus, they are
essentially independent of CP1 and the CTD. The surprising
activation of theUrzyme by theD146Amutation (19) neverthe-
less implies that the Urzyme mechanism differs from that of
full-length TrpRS. The highly conserved (42) core motif in the
N-terminal 46 residues of the Urzyme (i.e. the D1 switch motif
(43)), which also includes the ATP-binding site, was indepen-
dently identified as an important allosteric activator of the cat-
alytic Mg2 ion in full-length TrpRS (28). Although this core is
intact in the Urzyme, its function may differ substantially,
because of the fact that theCTD,whose relativemotion appears
to be critical to the activation of the metal ion in full-length
TrpRS, is entirely missing in the Urzyme. The two effects are
possibly related.Absence of theCTD in theUrzyme could allow
Asp-146 (Asp-68) to impede catalysis by stabilizing a nonpro-
ductive configuration of themetal ion (55).We suggest that the
catalytic importance of the Asp-146 residue in intact TrpRS
may be linked to the allosteric mechanism, which cannot func-
tion in the Urzyme.
These effects represent novel cryptic specificity and/or
catalytic enhancements that have been revealed by study of
the TrpRS Urzyme. The various putative enhancements pro-
vided by CP1 and the CTD to substrate recognition and
catalysis can now be investigated experimentally by straight-
forward genetic construction, because the catalytic activity of
the Urzyme itself can be measured. Similar experiments, in
which the authors restored the truncatedC-terminal domain in
trans and measured enhanced acylation activity, have been
reported for GluRS (34). Using Rosetta to redesign the inter-
faces of free CP1 and CTD to the DES Urzyme should facilitate
testing their activity in trans to compare covalent versus non-
covalent complementation.
Urzyme Kinetic Parameters Are Consistent with Those
Expected for the Earliest Synthetases and Confirm a Key Predic-
tion of the Rodin-Ohno Hypothesis—The TrpRS Urzyme accel-
erates tryptophan activation by 109–1010-fold, and this activ-
ity resides in the most highly conserved structural module of
the class I aaRS superfamily. Such rate enhancement repre-
sents a substantial selective advantage over, for example, puta-
tive ribozymal catalysts (56). Application of Ockham’s razor
thus implies that ancestral class I aaRSs resembled the TrpRS
Urzymemore closely than they did any radically different struc-
ture and that CP1 and the CTD were later additions that
enhanced specificity, respectively, for cognate amino acids and
tRNAs.
It was certainly essential that ATP be bound productively to
primordial aaRSs. The native-like ATP binding affinity of the
TrpRS Urzyme is thus consistent with its being a candidate for
the ancestral synthetase. Moreover, there is considerable pre-
cedent for the relatively high ATP affinity for the Urzyme. Hol
et al. (57) noted that phosphate-binding sites tend to occur at
the N terminus of -helices, because of the electrostatic poten-
tial of the four free amide nitrogen groups. Roughly 40% of the
Urzyme mass consists of a core motif found to be remarkably
intact in 110 families of Rossmannoid proteins (42), and
which contains, intact, the initial ATP-binding site of the native
enzyme (58). Titration of ATPwith the homologous 51-residue
Walker A segment from the F1-ATPase revealed that that pep-
tide binds ATP with Kd  10 M (59). We expressed and puri-
fied the corresponding TrpRS fragment, and it also binds ATP
more tightly than does full-length TrpRS.3
By confirming a key prediction that catalytic activity is largely
independent of CP1 and the CTD, the TrpRS Urzyme activ-
ity affords the first evidential support for the Rodin-Ohno
hypothesis. Differences in structure and catalytic mecha-
nism (e.g. tRNA acceptor stem-binding mode and hydroxyl
group specificity) strongly support the consensus that class I
and II aaRS had two distinct ancestors (2). However, trans-
lation of the reverse complements of nucleic acid sequences
coding for the conserved motifs of one class shows distinctly
nonrandom homology to the signature sequences of the other
class (18), suggesting that their ancestral gene sequences were
complementary.
Carter and Duax (61) produced circumstantial evidence for
the sense/antisense coding hypothesis by noting that class I and
II aaRS structures might resemble those of Achlya klebsiana
glutamate dehydrogenase and HSP70 chaperonin (a stress pro-
tein), respectively. The latter two proteins are reported to be
translation products from complementary strands of the same
contemporary gene (62–64). This interesting observation gen-
erated controversial feedback as Williams et al. (65) recently
challenged the conclusion that the A. klebsiana gene actually
does code for the dehydrogenase. Further analysis of that gene,
however (66), reinforces our original claim.
At first glance, the idea that the two synthetase classes orig-
inated from two complementary strands of one gene is very
3 L. Li, V. Weinreb, and C. W. Carter, Jr., manuscript in preparation.
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unusual, because favorable mutations on one strand would
likely be deleterious (e.g. lethal or nonsense) to the product
encoded by the opposite strand. However, especially in a pre-
cellular environment, coding both classes of aaRS classes on
one gene would make efficient use of genetic material. More
importantly, simultaneous expression of two synthetases with
complementary specificities (19, 66) would favor relatively
nonspecific translation of molten globular gene products from
RNAs in their immediate environment. Only later, as the
genetic code became firmly established and modern globular
proteins assumed more specific structures, would it have been
necessary to evolve higher amino acid specificity.
Multiple events of duplication, fusion, and insertion proba-
bly assembled the additional domains, enhancing substrate
affinity, fidelity, and rate enhancements of the primitive
enzymes. The remarkably idiosyncratic structure, mechanism,
and accessory functions (4) of the 20 contemporary aaRSs
resulted from this postulated divergent evolution. Themeasur-
able catalytic activity of the TrpRS Urzyme provides a key met-
ric for experimental recapitulation of the evolutionary motif
shuffling that likely served as a keymechanism to accelerate the
evolutionary adaptation and functional improvement of pri-
mordial protein catalysts (67).
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